Targeting cancer cells in the head and neck with a new treatment approach.
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor
This study is testing a new treatment that aims to block a protein called STAT3, which helps head and neck cancer cells grow, with the hope that it will make the cancer easier to treat while protecting healthy cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10903754 on NIH RePORTER |
What this research studies
This research focuses on developing a novel small-molecule inhibitor that targets STAT3, a protein involved in the growth and survival of head and neck cancer cells. By inhibiting STAT3, the research aims to disrupt the adverse tumor microenvironment that supports cancer progression. Patients may benefit from this approach as it could lead to more effective treatments that specifically target cancer cells while minimizing damage to healthy tissue. The methodology involves laboratory experiments and clinical trials to evaluate the safety and efficacy of the new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with head and neck cancer who have not responded well to existing treatments.
Not a fit: Patients with cancers unrelated to the head and neck or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted therapy for patients with head and neck cancer, potentially improving treatment outcomes.
How similar studies have performed: Other research has shown promising results with similar approaches targeting STAT3 in various cancers, indicating potential for success in this area.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Tweardy, David John — University of Tx Md Anderson Can Ctr
- Study coordinator: Tweardy, David John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.